UroGen Pharma Ltd. - Ordinary Shares (URGN): Price and Financial Metrics
GET POWR RATINGS... FREE!
URGN POWR Grades
- Growth is the dimension where URGN ranks best; there it ranks ahead of 75.37% of US stocks.
- URGN's strongest trending metric is Stability; it's been moving up over the last 179 days.
- URGN ranks lowest in Momentum; there it ranks in the 4th percentile.
URGN Stock Summary
- UROGEN PHARMA LTD's capital turnover -- a measure of revenue relative to shareholder's equity -- is better than only 4.94% of US listed stocks.
- URGN's equity multiplier -- a measure of assets relative to shareholders'equity -- is greater than that of merely 3.19% of US stocks.
- With a year-over-year growth in debt of 11,868.51%, UROGEN PHARMA LTD's debt growth rate surpasses 99.65% of about US stocks.
- Stocks with similar financial metrics, market capitalization, and price volatility to UROGEN PHARMA LTD are ARDX, EMKR, DZSI, MRIN, and WISA.
- URGN's SEC filings can be seen here. And to visit UROGEN PHARMA LTD's official web site, go to www.urogen.com.
URGN Valuation Summary
- In comparison to the median Healthcare stock, URGN's price/sales ratio is 40% higher, now standing at 2.8.
- Over the past 68 months, URGN's price/sales ratio has gone down 7.6.
Below are key valuation metrics over time for URGN.
| Stock | Date | P/S | P/B | P/E | EV/EBIT |
|---|---|---|---|---|---|
| URGN | 2022-11-25 | 2.8 | -2.8 | -1.6 | -2.2 |
| URGN | 2022-11-23 | 2.8 | -2.8 | -1.6 | -2.2 |
| URGN | 2022-11-22 | 2.8 | -2.8 | -1.6 | -2.2 |
| URGN | 2022-11-21 | 2.9 | -2.8 | -1.6 | -2.2 |
| URGN | 2022-11-18 | 3.1 | -3.1 | -1.8 | -2.3 |
| URGN | 2022-11-17 | 2.9 | -2.9 | -1.7 | -2.2 |
URGN's Quality Factors
The “Quality” component of the POWR Ratings focuses on 31 different factors of a companies fundamentals and operational strength. Here are some key insights as we drill into the specifics of these quality attributes.- URGN has a Quality Grade of D, ranking ahead of 11.82% of graded US stocks.
- URGN's asset turnover comes in at 0.249 -- ranking 178th of 682 Pharmaceutical Products stocks.
- BIIB, TECH, and ZGNX are the stocks whose asset turnover ratios are most correlated with URGN.
The table below shows URGN's key quality metrics over time.
| Period | Asset Turnover | Gross Margin | ROIC |
|---|---|---|---|
| 2021-06-30 | 0.249 | 0.897 | -1.677 |
| 2021-03-31 | 0.148 | 0.901 | -1.535 |
| 2020-12-31 | 0.080 | 0.914 | -1.308 |
| 2020-09-30 | 0.023 | 0.907 | -1.202 |
| 2020-06-30 | 0.002 | 0.871 | -1.036 |
| 2020-03-31 | 0.000 | 1.000 | -0.926 |
URGN Price Target
For more insight on analysts targets of URGN, see our URGN price target page. And for a list of of all stocks sorted by upside potential based on analyst target price, see our Top Price Target page.
| Average Price Target | $42.60 | Average Broker Recommendation | 1.33 (Strong Buy) |
URGN Stock Price Chart Interactive Chart >
URGN Price/Volume Stats
| Current price | $8.39 | 52-week high | $12.63 |
| Prev. close | $8.73 | 52-week low | $4.85 |
| Day low | $8.20 | Volume | 45,200 |
| Day high | $8.93 | Avg. volume | 119,175 |
| 50-day MA | $9.84 | Dividend yield | N/A |
| 200-day MA | $8.14 | Market Cap | 190.80M |
UroGen Pharma Ltd. - Ordinary Shares (URGN) Company Bio
UroGen Pharma Ltd., a clinical stage biopharmaceutical company, focuses on developing therapies for urological pathologies. The company is developing its product candidates as chemoablation agents, which are designed to remove tumors by non-surgical means, to treat several forms of non-muscle invasive urothelial cancer, including low-grade upper tract urothelial carcinoma, and low-grade bladder cancer. The company was founded in 2004 and is based in Raanana, Israel.
Latest URGN News From Around the Web
Below are the latest news stories about UROGEN PHARMA LTD that investors may wish to consider to help them evaluate URGN as an investment opportunity.
UroGen Pharma to Present at Evercore ISI 5th Annual Virtual HealthCONx ConferencePRINCETON, N.J., November 21, 2022--UroGen Pharma Ltd. (Nasdaq: URGN), a biotech company dedicated to developing and commercializing innovative solutions that treat urothelial and specialty cancers, today announced that it will participate in a virtual fireside chat at the upcoming Evercore ISI 5th Annual HealthCONx Conference on November 29, 2022 at 3:55 PM ET. |
Some Analysts Just Cut Their UroGen Pharma Ltd. (NASDAQ:URGN) EstimatesToday is shaping up negative for UroGen Pharma Ltd. ( NASDAQ:URGN ) shareholders, with the analysts delivering a... |
UroGen Highlights New Real-World Safety Data Published in The British Journal of Urology International That Showed a Low Rate of Ureteral Stenosis When Antegrade Administration of JELMYTO® was Used in Patients with Upper Tract Urothelial CarcinomaPRINCETON, N.J., November 14, 2022--UroGen Highlights New Real-World Safety Data from a Retrospective Study Published in The British Journal of Urology International |
UroGen Pharma Third Quarter 2022 Earnings: EPS Beats Expectations, Revenues LagUroGen Pharma ( NASDAQ:URGN ) Third Quarter 2022 Results Key Financial Results Revenue: US$16.1m (up 42% from 3Q 2021... |
Urogen Pharma (URGN) Reports Q3 Loss, Lags Revenue EstimatesUrogen Pharma (URGN) delivered earnings and revenue surprises of 7.38% and 20.69%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock? |
URGN Price Returns
| 1-mo | -28.29% |
| 3-mo | 10.69% |
| 6-mo | 35.54% |
| 1-year | -26.98% |
| 3-year | -73.09% |
| 5-year | -79.25% |
| YTD | -11.78% |
| 2021 | -47.23% |
| 2020 | -46.00% |
| 2019 | -22.50% |
| 2018 | 15.72% |
| 2017 | N/A |
Loading social stream, please wait...